{"title":"Diagnosing and monitoring CKD in practice","authors":"Robert Lewis","doi":"10.3132/PCCJ.2009.027","DOIUrl":"https://doi.org/10.3132/PCCJ.2009.027","url":null,"abstract":"","PeriodicalId":308856,"journal":{"name":"Primary Care Cardiovascular Journal (pccj)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114201051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Robin Thompson, C. O'regan, S. Morant, Berkeley S. Phillips, Seleen Ong
Objective: Current baseline cholesterol data in the UK are limited to values obtained from clinical trials or from surveys of the general population. However, baseline cholesterol data from the statin-treated population may be more appropriate when estimating the impact of alternative statin prescribing strategies. This study set out to determine the baseline cholesterol measurement before patients are started on a statin. Design: Data from The Health Improvement Network were used to identify statin users. The baseline cholesterol measurement prior to the first prescription of a statin was recorded for 223,058 statin-treated patients, stratified by cardiovascular risk. Results: The mean total cholesterol (TC) value for the primary prevention group was 6.57 mmol/L (standard deviation [SD] 1.19), whereas patients with pre-existing cardiovascular disease (CVD) and those with diabetes were found to have mean TC levels of 6.1 mmol/L (SD 1.16) and 5.9 mmol/L (SD 1.15), respectively. Overall, the mean TC (mmol/L) for the pooled statin-treated patient group was 6.3 mmol/L (SD 1.22). Conclusions: This study revealed differences in the mean baseline cholesterol levels for different cardiovascular risk groups. Overall, the mean baseline cholesterol measurement of the statin-treated population is higher than that of the general population. These new baseline cholesterol levels in statin-treated patients should facilitate more detailed assessments of alternative statin-prescribing strategies and their impact on achieving treatment targets.
{"title":"Measurement of baseline total cholesterol: new data from The Health Improvement Network (THIN) database","authors":"Robin Thompson, C. O'regan, S. Morant, Berkeley S. Phillips, Seleen Ong","doi":"10.3132/PCCJ.2008.028","DOIUrl":"https://doi.org/10.3132/PCCJ.2008.028","url":null,"abstract":"Objective: Current baseline cholesterol data in the UK are limited to values obtained from clinical trials or from surveys of the general population. However, baseline cholesterol data from the statin-treated population may be more appropriate when estimating the impact of alternative statin prescribing strategies. This study set out to determine the baseline cholesterol measurement before patients are started on a statin. Design: Data from The Health Improvement Network were used to identify statin users. The baseline cholesterol measurement prior to the first prescription of a statin was recorded for 223,058 statin-treated patients, stratified by cardiovascular risk. Results: The mean total cholesterol (TC) value for the primary prevention group was 6.57 mmol/L (standard deviation [SD] 1.19), whereas patients with pre-existing cardiovascular disease (CVD) and those with diabetes were found to have mean TC levels of 6.1 mmol/L (SD 1.16) and 5.9 mmol/L (SD 1.15), respectively. Overall, the mean TC (mmol/L) for the pooled statin-treated patient group was 6.3 mmol/L (SD 1.22). Conclusions: This study revealed differences in the mean baseline cholesterol levels for different cardiovascular risk groups. Overall, the mean baseline cholesterol measurement of the statin-treated population is higher than that of the general population. These new baseline cholesterol levels in statin-treated patients should facilitate more detailed assessments of alternative statin-prescribing strategies and their impact on achieving treatment targets.","PeriodicalId":308856,"journal":{"name":"Primary Care Cardiovascular Journal (pccj)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123933444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Give medical therapy a chance","authors":"A. Begg","doi":"10.3132/PCCJ.2009.007","DOIUrl":"https://doi.org/10.3132/PCCJ.2009.007","url":null,"abstract":"","PeriodicalId":308856,"journal":{"name":"Primary Care Cardiovascular Journal (pccj)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124013796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Implementing the NICE guideline for secondary prevention of MI","authors":"J. Skinner","doi":"10.3132/PCCJ.2008.038","DOIUrl":"https://doi.org/10.3132/PCCJ.2008.038","url":null,"abstract":"","PeriodicalId":308856,"journal":{"name":"Primary Care Cardiovascular Journal (pccj)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129982498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The European perspective","authors":"R. Hobbs","doi":"10.3132/PCCJ.2008.018","DOIUrl":"https://doi.org/10.3132/PCCJ.2008.018","url":null,"abstract":"","PeriodicalId":308856,"journal":{"name":"Primary Care Cardiovascular Journal (pccj)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131168502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Prasugrel: the evidence supporting NICE’s recommendation for the treatment of acute coronary syndromes (ACS)","authors":"M. Kirby","doi":"10.3132/PCCJ.2010.024","DOIUrl":"https://doi.org/10.3132/PCCJ.2010.024","url":null,"abstract":"","PeriodicalId":308856,"journal":{"name":"Primary Care Cardiovascular Journal (pccj)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125387376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Rosiglitazone: how should we be using this oral hypoglycaemic drug after studies indicating increased MI risk have resulted in changes in recommendations?","authors":"B. Karet","doi":"10.3132/PCCJ.2008.004","DOIUrl":"https://doi.org/10.3132/PCCJ.2008.004","url":null,"abstract":"","PeriodicalId":308856,"journal":{"name":"Primary Care Cardiovascular Journal (pccj)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126906531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"C-reactive protein as a marker of cardiovascular risk. Chicken, egg or turkey?","authors":"B. Karet","doi":"10.3132/PCCJ.2008.036","DOIUrl":"https://doi.org/10.3132/PCCJ.2008.036","url":null,"abstract":"","PeriodicalId":308856,"journal":{"name":"Primary Care Cardiovascular Journal (pccj)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132840280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：